Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Everolimus

Everolimus

Introduction Everolimus is a derivative of sirolimus (also known as rapamycin) and belongs to the class of mammalian target of rapamycin (mTOR) inhibitors. It is an important immunosuppressive and anticancer agent used in various therapeutic settings, from organ transplantation to the treatment of cancers and rare genetic disorders. Due to its wide range of applications, Everolimus has become a staple in both oncology and transplant medicine.

Chemical and Pharmacological Profile

Everolimus (C53H83NO14) is a macrolide compound with immunosuppressive and antiproliferative properties. As an mTOR inhibitor, it interferes with the mTORC1 complex, which plays a critical role in cell growth, proliferation, metabolism, and angiogenesis.

Mechanism of Action

Everolimus binds to the cytosolic protein FKBP-12 to form a complex that inhibits mTORC1. This inhibition leads to the suppression of downstream signaling pathways, such as the phosphorylation of S6 kinase and 4EBP1. The net result is a reduction in protein synthesis, cell growth, and angiogenesis. In cancer cells, this results in anti-proliferative effects, while in immune cells, it reduces activation and proliferation.

Clinical Applications

  1. Organ Transplantation Everolimus is used to prevent organ rejection in kidney and liver transplant recipients. It helps maintain immune tolerance while reducing the need for high doses of calcineurin inhibitors, which are associated with nephrotoxicity. In combination with cyclosporine and corticosteroids, Everolimus provides effective immunosuppression.

  2. Oncology

    • Renal Cell Carcinoma (RCC): Approved for advanced RCC after failure of treatment with VEGF-targeted therapies.

    • Hormone Receptor-Positive, HER2-Negative Breast Cancer: Used in combination with exemestane in postmenopausal women whose disease has progressed after treatment with non-steroidal aromatase inhibitors.

    • Neuroendocrine Tumors (NETs): Indicated for advanced NETs of pancreatic, gastrointestinal, or lung origin.

    • Subependymal Giant Cell Astrocytoma (SEGA): Used in patients with tuberous sclerosis complex (TSC) who are not candidates for surgical resection.

  3. Tuberous Sclerosis Complex (TSC) Everolimus is approved for treating TSC-associated SEGA and renal angiomyolipomas. TSC is characterized by benign tumors in multiple organs, and mTOR pathway dysregulation plays a central role in its pathophysiology.

Dosage and Administration

Everolimus is available in both tablet and dispersible tablet forms. The dosage depends on the indication, patient’s body surface area, and therapeutic drug monitoring. For transplant indications, doses are typically lower and adjusted based on trough blood levels. For cancer, higher doses are used, and continuous daily dosing is common.

Pharmacokinetics

  • Absorption: Oral bioavailability is moderate; food affects its absorption.

  • Distribution: Widely distributed with high plasma protein binding.

  • Metabolism: Metabolized by CYP3A4 and is a substrate of P-glycoprotein.

  • Elimination: Excreted primarily via feces; half-life ranges between 30-60 hours.

Adverse Effects

  1. Common Adverse Effects:

    • Stomatitis

    • Rash

    • Fatigue

    • Diarrhea

    • Infections

    • Peripheral edema

  2. Serious Adverse Effects:

    • Non-infectious pneumonitis

    • Renal dysfunction

    • Hyperglycemia

    • Hyperlipidemia

    • Impaired wound healing

Monitoring Parameters

Patients on Everolimus therapy require regular monitoring, including:

  • Complete blood counts (CBC)

  • Renal and liver function tests

  • Fasting lipid profile

  • Blood glucose

  • Trough blood levels (especially in transplant patients)

Drug Interactions

Everolimus is a CYP3A4 substrate, and co-administration with CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) can increase blood levels, raising the risk of toxicity. Inducers like rifampin can reduce effectiveness. Caution is advised when used with other nephrotoxic or myelosuppressive agents.

Contraindications and Precautions

  • Hypersensitivity to Everolimus or other rapamycin derivatives

  • Severe hepatic impairment (dose adjustment needed)

  • Active infections or recent major surgery

  • Use in pregnancy and lactation is not recommended due to teratogenic potential

Everolimus in Clinical Trials and Research

Ongoing studies are exploring Everolimus in various cancers, such as hepatocellular carcinoma, glioblastoma multiforme, and endometrial cancer. Researchers are also investigating its use in combination with other targeted therapies and immune checkpoint inhibitors to enhance efficacy and overcome resistance.

Resistance and Limitations

While Everolimus has shown promise, resistance can develop, especially in oncology. Feedback activation of upstream pathways and mTORC2 involvement may limit its efficacy. Combination therapies and second-generation mTOR inhibitors are being developed to address these challenges.

Patient Education and Counseling

Patients should be informed about:

  • The importance of adherence to prescribed dosage

  • Potential side effects like mouth ulcers and signs of infection

  • Avoiding grapefruit juice (CYP3A4 interaction)

  • Need for regular monitoring and follow-ups

Cost and Accessibility

Everolimus is a high-cost medication, especially in oncology. Generic formulations are becoming available, which may help reduce costs. Insurance coverage and patient assistance programs are critical for access in many regions.

Global and Regulatory Status

Everolimus is marketed under various brand names like Afinitor (oncology), Zortress (transplantation), and Votubia (TSC-related conditions). It is approved by the FDA, EMA, and other global regulatory agencies for multiple indications.

Conclusion

Everolimus stands as a versatile and vital medication across several medical disciplines. Its unique mechanism of action via mTOR inhibition allows it to be effective in diverse diseases, from cancer to organ transplantation and genetic disorders like TSC. As research continues to evolve, Everolimus is expected to retain a central role in modern therapeutics, potentially expanding its utility in novel combinations and indications. However, careful monitoring, management of adverse effects, and attention to drug interactions remain essential for optimizing outcomes.